Comparative Effectiveness Needs Holistic Value Measures – Amgen Exec
Executive Summary
As momentum for payers to put more emphasis on pharmaceuticals' comparative effectiveness data, those involved in implementing CE programs need to recognize the "multi-dimensional" aspect of a drug's value, Amgen VP of Global Coverage & Reimbursement and Global Health Economics Josh Ofman said
You may also be interested in...
BIO Taps Big Pharma Execs for Federal Comparative Effectiveness Research Board Nominations
Four of BIO's six nominations are also PhRMA's nominations for the Patient-Centered Outcomes Research Institute board of governors.
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.